Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

被引：0
|
作者：
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
机构：
[1] Sarah Cannon Research Institute and the Tennessee Oncology,Department of Surgery, Oncology and Gastroenterology
[2] PLLC,undefined
[3] University of Pittsburgh Medical Center,undefined
[4] Weston Park Hospital,undefined
[5] Sheffield Cancer Research Center,undefined
[6] University of Padova,undefined
[7] Padova,undefined
[8] and Istituto Oncologico Veneto IRCCS,undefined
[9] Vall d’Hebron Institute of Oncology (VHIO),undefined
[10] Celgene Corporation,undefined
[11] Centre de Lutte Contre le Cancer d’Auvergne,undefined
[12] Texas Oncology-Baylor Charles A. Sammons Center; US Oncology,undefined
[13] Breast Center,undefined
[14] University of Munich,undefined
来源：
Trials | / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
    Tabernero, Josep
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl N.
    Romano, Alfredo
    Ferrara, Stefano
    Von Hoff, Daniel D.
    ONCOLOGIST, 2015, 20 (02): : 143 - 150
  • [32] A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
    M Harries
    C Moss
    T Perren
    M Gore
    G Hall
    M Everard
    R A'Hern
    I Gibbens
    A Jenkins
    R Shah
    C Cole
    O Pizzada
    S Kaye
    British Journal of Cancer, 2004, 91 : 627 - 632
  • [33] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [34] Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer
    Zhang, J.
    Lin, Y.
    Sun, X. J.
    Wang, B. Y.
    Wang, Z. H.
    Luo, J. F.
    Wang, L. P.
    Zhang, S.
    Cao, J.
    Tao, Z. H.
    Wu, J.
    Shao, Z. M.
    Yang, W. T.
    Hu, X. C.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1741 - 1747
  • [35] TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer
    Awada, A. H.
    Cortes, J.
    Slater, S.
    Macpherson, I.
    Csoszi, T.
    Bertrand, J. -B.
    Clermont, A. -S.
    Pollard, R.
    Chrestia-Blanchine, R.
    Biswas-Baldwin, N.
    Youssoufian, H.
    El-Hariry, I.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
    Hernandez-Aya, Leonel Fernando
    Gao, Feng
    Goedegebuure, Peter S.
    Ma, Cynthia X.
    Ademuyiwa, Foluso Olabisi
    Park, Haeseong
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Bose, Ron
    Gillanders, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Hao, Chunfang
    He, Lihong
    Dong, Guolei
    Wang, Xiaorui
    Jia, Yongsheng
    Zhang, Li
    CANCER RESEARCH, 2015, 75
  • [38] Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.
    Lo, S. S.
    Guo, R.
    Czaplicki, K. L.
    Robinson, P. A.
    Gaynor, E.
    Barhamand, F. B.
    Schulz, W. C.
    Kash, J. J.
    Horvath, L. E.
    Bayer, R. A.
    Petrowsky, C.
    De la Torre, R.
    Park, J. H.
    Albain, K. S.
    CANCER RESEARCH, 2012, 72
  • [39] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
    Emens, Leisha A.
    Adams, Sylvia
    Loi, Sherene
    Schneeweiss, Andreas
    Rugo, Hope S.
    Winer, Eric P.
    Barrios, Carlos H.
    Dieras, Veronique
    de la Haba-Rodriguez, Juan
    Gianni, Luca
    Chui, Stephen Y.
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group
    Saloustros, Emmanouil
    Nikolaou, Michail
    Kalbakis, Konstantinos
    Polyzos, Aris
    Christofillakis, Charalampos
    Kentepozidis, Nikolaos
    Pistamaltzian, Nikolaos
    Kourousis, Charalampos
    Vamvakas, Lampros
    Georgoulias, Vasilios
    Mavroudis, Dimitris
    CLINICAL BREAST CANCER, 2018, 18 (01) : 88 - 94
12345